更新于：2024-12-17
Teicoplanin
替考拉宁
更新于：2024-12-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、孤儿药 (美国) |
登录后查看时间轴
关联
37
项与 替考拉宁 相关的临床试验Use of Teicoplanin on a Three-weekly Administration in the Complex Outpatient Macroactivity Regimen of Infectious Diseases Unit in the Alessandro Manzoni Hospital (Lecco, Italy)
An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS - study to evaluate the safety of inhaled Teicoplanin in the treatment of Stafilococco infections
A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care
100 项与 替考拉宁 相关的临床结果
登录后查看更多信息
100 项与 替考拉宁 相关的转化医学
登录后查看更多信息
100 项与 替考拉宁 相关的专利（医药）
登录后查看更多信息
4,121
项与 替考拉宁 相关的文献（医药）2024-12-05Microbiology Spectrum
Biofilm-mediated antibiotic tolerance in
Staphylococcus aureus
from spinal cord stimulation device-related infections
Article
作者: Abril, Elva ; Arcioni, Roberto ; Sivori, Francesca ; Cavallo, Ilaria ; Pimpinelli, Fulvia ; Santino, Iolanda ; Pelagalli, Lorella ; Mariani, Valerio ; Di Domenico, Enea Gino ; De Blasi, Roberto Alberto ; Truglio, Mauro ; Toma, Luigi ; Solmone, Mariacarmela ; Fradiani, Piera Assunta ; Fabrizio, Giorgia
ABSTRACT:
Staphylococcus aureus
is a predominant cause of infections in individuals with spinal cord stimulation (SCS) devices. Biofilm formation complicates these infections, commonly requiring both surgical and antibiotic treatments. This study explored the biofilm matrix composition and antimicrobial susceptibility of planktonic and biofilm-growing
S. aureus
isolates from individuals with SCS-related infections. Whole-genome sequencing (WGS) examined genotypes, virulome, resistome, and the pan-genome structure. The study also analyzed biofilm matrix composition, early surface adhesion, hemolytic activity, and antibiotic-susceptibility testing. WGS revealed genetic diversity among isolates. One isolate, though oxacillin susceptible, contained the
mec
A gene. The median number of virulence factor genes per isolate was 58. All isolates harbored the biofilm-related
ica
A/D genes. When assessing phenotypic characteristics, all strains demonstrated the ability to form biofilms
in vitro
. The antimicrobial susceptibility profile indicated that oxacillin, rifampin, and teicoplanin showed the highest efficacy against
S. aureus
biofilm. Conversely, high biofilm tolerance was observed for vancomycin, trimethoprim/sulfamethoxazole, and levofloxacin. These findings suggest that
S. aureus
isolates are highly virulent and produce robust biofilms. In cases of suspected biofilm infections caused by
S. aureus
, vancomycin should not be the primary choice due to its low activity against biofilm. Instead, oxacillin, rifampin, and teicoplanin appear to be more effective options to manage SCS infections.
IMPORTANCE:
SCS devices are increasingly used to manage chronic pain, but infections associated with these devices, particularly those caused by
Staphylococcus aureus
, present significant clinical challenges. These infections are often complicated by biofilm formation, which protects bacteria from immune responses and antibiotic treatments, making them difficult to eradicate. Understanding the genetic diversity, virulence, and biofilm characteristics of
S. aureus
isolates from SCS infections is critical to improving treatment strategies. Our study highlights the need to reconsider commonly used antibiotics like vancomycin, which shows reduced activity against biofilm-growing cells. Identifying more effective alternatives, such as oxacillin, rifampin, and teicoplanin, provides valuable insight for clinicians when managing biofilm-related
S. aureus
infections in patients with SCS implants. This research contributes to the growing evidence that biofilm formation is crucial in treating device-related infections, emphasizing the importance of tailoring antimicrobial strategies to the biofilm phenotype.
2024-12-01THERAPEUTIC DRUG MONITORING
Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis
Article
作者: Ueda, Takashi ; Oda, Kazutaka ; Uekusa, Shusuke ; Nishimura, Koji ; Hanai, Yuki ; Murakami, Lisa ; Matsumoto, Kazuaki ; Ohashi, Hayato ; Takesue, Yoshio ; Matsuo, Kazuhiro
Background::
Teicoplanin is used to treat serious Gram-positive bacterial infections. However, the optimal trough concentrations for pediatric patients remain unclear owing to the lack of monitoring guidelines. This study aimed to determine the optimal teicoplanin trough concentration for treating Gram-positive bacterial infections in children.
Methods::
A systematic review was conducted using 4 databases. Stepwise cutoffs within the range of 10–30 mcg/mL were used for efficacy and safety. Studies were included if they reported treatment success rates and/or all-cause mortality, nephrotoxicity, hepatotoxicity, and thrombocytopenia according to the trough concentration.
Results::
The meta-analysis included 12 studies involving 830 pediatric patients. Teicoplanin cutoff values of 10, 15, 20, and 30 mcg/mL were reported in 9, 8, 9, and 2 studies, respectively. Trough concentrations <10 mcg/mL significantly reduced the treatment success rate, with an odds ratio of 0.07 and a 95% confidence interval ranging from 0.01 to 0.40. The overall treatment success rate was 50.0% versus 95.7% observed at concentrations ≥10 mcg/mL. However, no significant difference was observed at the 15-, 20-, and 30-mcg/mL cutoffs, when compared with lower concentrations. Trough concentrations <20 mcg/mL were associated with a decreased risk of nephrotoxicity (odds ratio = 0.21; 95% confidence interval, 0.08–0.55). However, hepatotoxicity and thrombocytopenia showed no significant associations with trough concentration ranges between 10 and 30 mcg/mL.
Conclusions::
Although further prospective studies are required for validation, the authors' findings suggest that 10- to 20-mcg/mL teicoplanin is the optimal trough concentration for enhanced clinical success and reduced toxicity in pediatric patients.
2024-12-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Chiral superficially porous stationary phases for enantiomeric separation of condensed 1,4-dihydropyridine derivatives
Article
作者: Armstrong, Daniel W ; Burk, Ryan Jacob ; Salehi, Reza ; Gündüz, Miyase Gözde ; J, Siddharth Jaya Sajeevan ; Berthod, Alain ; Armstrong, Daniel W.
1,4-dihydropyridine (DHP) scaffold occupies a prominent position among all heterocyclic compounds owing to its versatile pharmacological properties, particularly its well-known calcium channel blocking activity. In the quest of developing new calcium channel blockers, fifty seven 5-oxo-hexahydroquinoline (HHQ) derivatives carrying DHP framework in a condensed ring system were recently synthesized as racemic mixtures. Due to their potential as drug candidates, enantiomers arising from the asymmetric center at the C-4 position of the HHQ ring were separated. Four modern columns packed with 2.7 µm superficially porous particles bonded with a chiral selector were used. The chiral selectors were three macrocyclic glycopeptide selectors: vancomycin, teicoplanin, and a macrocyclic derivative called nico. The fourth bonded selector was the dinitrobenzamido-tetrahydrophenanthrenyl derivative called Whelko. The four chromatographic modes were assayed with the mobile phase compositions: reversed phase with acetonitrile/buffer 30/70 %v/v, normal phase with hexane/ethanol 80/20 %v/v, and subcritical fluid chromatography with CO2/methanol 80/20 %v/v at 25 °C. The WhelkoShell column was the most effective in separating this set of 57 compounds. Several enantioresolution factors passed 20 with enantioselectivity ratios higher than 4. Molecular modeling showed that the compounds had a T-shape that fitted well the molecular structure of the WhelkoShell selector in the normal or subcritical modes. Additionally, seven compounds had a second chiral center. The NicoShell column was able to separate all four stereoisomers of these compounds in the reversed phase mode. The preparative production of pure enantiomers of these compounds would be straightforward using the WhelkoShell column in the subcritical mode.
100 项与 替考拉宁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 | |
| 囊性纤维化 | 临床1期 | 意大利 | 2019-10-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | antistaphylococcal drugs (Group 1 (positive initial BC for S.aureus)) | 壓齋網廠鏇獵鏇糧網遞(窪醖鑰膚簾網襯鹹憲鹹) = 築觸簾觸鏇餘糧觸夢壓 鬱憲衊繭積襯鹹憲鬱鑰 (襯選築淵廠膚觸鹹夢遞 ) 更多 | - | 2024-02-23 | ||
antistaphylococcal drugs (Group 2 (negative BC for S.aureus)) | 壓齋網廠鏇獵鏇糧網遞(窪醖鑰膚簾網襯鹹憲鹹) = 壓襯築壓艱築範夢鑰蓋 鬱憲衊繭積襯鹹憲鬱鑰 (襯選築淵廠膚觸鹹夢遞 ) 更多 | ||||||
临床4期 | 44 | Teicoplanin lock therapy | 醖窪構網繭鹽淵齋顧鬱(積鹹製齋窪積齋憲製遞) = 鹹夢壓糧鑰窪鹽遞壓鏇 顧餘積願艱齋積觸繭鏇 (窪夢夢顧鹽繭構憲觸遞 ) 更多 | 积极 | 2009-11-01 | ||
Vancomycin lock therapy | 醖窪構網繭鹽淵齋顧鬱(積鹹製齋窪積齋憲製遞) = 齋淵遞淵鏇鏇衊鑰壓餘 顧餘積願艱齋積觸繭鏇 (窪夢夢顧鹽繭構憲觸遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用